Investors
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
press release
July 17, 2019
Company remains on track to submit Nolasiban MAA in the fourth quarter of 2019 GENEVA, Switzerland and BOSTON, MA…
Read morepress release
Geneva, Switzerland and Boston, MA – July 12, 2019– ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the…
Read morepress release
Geneva, Switzerland and Boston, MA – July 8, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…
Read moreJune 29, 2023
May 18, 2022
ObsEva Announces Update on Board of Directors
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 –…
Read moreMedia
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840